Adipotide

Also known as: prohibitin-targeting peptide 1

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA

Randomized controlled trials 0 of 3 publications on PubMed

Registered clinical trials 1 0 active

Adverse event reports 0 0 classified as serious

Adipotide is not an FDA-approved drug: Drugs@FDA has no record of it.
PubMed lists 3 publications mentioning it, including 0 randomized controlled trials and 1 animal-only study.
ClinicalTrials.gov lists 1 registered study testing it (0 active).
FDA’s adverse event system (FAERS) has no reports mentioning it.

Research topics

Obesity 3
Peptidomimetics 3
Adipose Tissue, White 2
Insulin Resistance 2
Weight Loss 2
Absorptiometry, Photon 1
Adipocytes 1
Adiponectin 1
Adipose Tissue 1
Anthropometry 1

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 3
Human (MeSH) 2
Animal only 1
Clinical trials 0
Randomized controlled trials 0
Systematic reviews & meta-analyses 0
Case reports 0
Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Animal study 2013 Journal of controlled release : official journal of the Controlled Release Society
Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys". Human study 2012 Science translational medicine
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Human study 2011 Science translational medicine

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

Registered: 1
Active: 0
With posted results: 0

Conditions studied

Prostate Cancer 1

Study	Status	Phase	Start
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity NCT01262664 M.D. Anderson Cancer Center	Terminated	Phase 1	May 24, 2012

All 1 study on ClinicalTrials.gov ↗

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

No FAERS reports mention this peptide.

Source: FDA FAERS · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.